Adriamycin
B-Cell Non-Hodgkin Lymphoma
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Mwanasha Merrill, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588698CT.gov Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07097363CT.gov Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06824701CT.gov Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Suspended | — | — | — |
NCT07081022CT.gov JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | — | Recruiting | — | — | — |
NCT07168980CT.gov Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents | — | Recruiting | — | — | — |
NCT06742996CT.gov A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | — | Recruiting | — | — | — |
NCT06564038CT.gov A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06646666CT.gov ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | — | Not Yet Recruiting | — | — | — |
NCT06634589CT.gov A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06695013CT.gov Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL | — | Recruiting | — | — | — |
Show 35 more trialsShow fewer
NCT05873712CT.gov Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | — | Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05270057CT.gov Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | — | Active Not Recruiting | — | — | — |
NCT05797948CT.gov GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT05202782CT.gov Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05201248CT.gov A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04594798CT.gov A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | — | Active Not Recruiting | — | — | — |
NCT04884035CT.gov Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | — | Recruiting | — | — | — |
NCT05097443CT.gov Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05164770CT.gov Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04257578CT.gov Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03995147CT.gov Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04094142CT.gov Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT04152577CT.gov R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL | — | Unknown | — | — | — |
NCT03677141CT.gov A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03467373CT.gov A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | — | Completed | — | — | — |
NCT03206671CT.gov Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | — | Active Not Recruiting | — | — | — |
NCT02670317CT.gov Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | — | Terminated | — | — | — |
NCT02787239CT.gov Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | — | Completed | — | — | — |
NCT02405676CT.gov BNHL-2015 for Children or Adolescents in China | — | Active Not Recruiting | — | — | — |
NCT02208037CT.gov Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | — | Completed | — | — | — |
NCT01925612CT.gov Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | — | Terminated | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01695941CT.gov Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01516580CT.gov Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | — | Completed | — | — | — |
NCT01414855CT.gov A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | — | Completed | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00498043CT.gov A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma | — | Completed | — | — | — |
NCT00455897CT.gov CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00379574CT.gov Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | — | Completed | — | — | — |
NCT00577629CT.gov Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | — | Completed | — | — | — |
NCT00054665CT.gov PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00147121CT.gov Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) | — | Completed | — | — | — |
NCT00051025CT.gov Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-b-cell-non-hodgkin-lymphoma-29691
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →